BioLink Therapeutics develops mechanism-driven therapies in oncology, neurodegeneration, and antimicrobial resistance — integrating biology, AI, and clinical insight.
BioLink Therapeutics is a next-generation drug development company solving complex diseases through biology-first, translational approaches.
"Driven by real-world challenges in neuroscience and oncology, BioLink aims to deliver therapies that are not just innovative, but clinically meaningful and globally accessible."
Multi-asset programs across three high-value therapeutic areas, each with a clear adjunct positioning strategy.
Targeting the tumor microenvironment and mitochondrial ROS modulation as an adjunct to standard chemotherapy and immunotherapy regimens.
Microbiome-mediated neuroimmune modulation targeting Parkinson's disease and related neurodegenerative disorders via systemic intervention.
Combating the global AMR crisis by enhancing efficacy of existing antibiotics through novel resistance pathway and bacterial survival mechanism targeting.
We combine cutting-edge tools and translational disease models to accelerate biology into actionable therapeutics.
We don't just discover drugs — we translate biology into clinically actionable therapies that are meaningful for patients and viable at scale.
Key DifferentiatorBioLink operates at the intersection of academia, clinical research, and industry to accelerate therapeutic impact globally.
We welcome partnerships across the full spectrum of drug development — from early discovery co-development to late-stage licensing and co-promotion arrangements with shared strategic objectives.
Start a ConversationA compelling portfolio built on strategic adjunct positioning, translational rigor, and cost-effective drug development.
Learn more about our pipeline, strategy, and the investment opportunity at BioLink Therapeutics.
Whether you're a potential partner, investor, or collaborator — we'd love to hear from you.